GSK805

GSK805 is an orally active and CNS penetrant RORγt inhibitor. GSK805 inhibits RORγ and Th17 cells differentiation with pIC 50 values of 8.4 and >8.2. GSK805 inhibits the function of Th17 cells. GSK805 can be used for the research of immunity In Vitro GSK805 (0.5 μM; 4 d) inhibits Th17 cell responses. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Differentiation AssayCell Line: CD4 + T cells Concentration: 0.5 μM Incubation Time: 4 days Result: Inhibited IL-17 production during Th17 cell differentiation. In Vivo GSK805 (10 mg/kg; p.o. once per day for 35 days) improves the situation of mice with experimental autoimmune encephalomyelitis (EAE). GSK805 (30 mg/kg; p.o. once) inhibits Th17 cell responses in EAE mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6 mice were immunized with MOG35–55 plus CFADosage: 10 mg/kg Administration: Oral gavage; 10 mg/kg once per day; for 35 days Result: Efficiently ameliorated the severity of EAE in mice. Animal Model: C57BL/6 mice with EAEDosage: 30 mg/kg Administration: Oral gavage; 30 mg/kg once Result: Reduced both IFN-γ - IL-17 + and IFN-γ + IL-17 + T cells without altered the frequency of TNF-α + T cells in EAE mice. IC50& Target:IC50: 8.4 (RORγt)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet